RESUMO
El día 30 de enero de 2020 la Organización Mundial de la Salud (OMS) reconoce la condición de pandemia por el virus SARS-CoV2 responsable de la enfermedad por coronavirus de 2019 (COVID-CoV2 por su denominación en inglés). Se ha demostrado que la vía respiratoria de pacientes infectados por COVID-19 tiene una alta carga viral, especialmente en nariz, garganta y tráquea. Los procedimientos que involucran el tracto aerodigestivo superior, como la broncoscopía, se consideran de alto riesgo de infección. Recomendaciones de diferentes sociedades establecen lineamientos para la realización de estos procedimientos, recomendando medidas de seguridad específicas evitando en lo posible la realización de broncoscopía rígida. Nuestra unidad corresponde a un servicio de neumonología intervencionista del sistema de salud público. Para hacer frente a la demanda de atención, necesidad de realizar procedimientos impostergables y una limitación en infraestructura y recursos, se inició un plan de contingencia y prueba de elementos alternativos orientados a potenciar la seguridad del personal y sus pacientes. Se presentan en este trabajo las medidas generales y nuevos dispositivos incluidos en nuestra secuencia de trabajo con el fin de mejorar la bioseguridad para el personal de salud y el paciente ante la necesidad de continuar realizando procedimientos.
On January 30, 2020, the World Health Organization (WHO) declares the pandemic of SARS-CoV2, responsible for the coronavirus disease of 2019 (COVID-CoV2). It has been shown that the airways of patients infected with COVID-19 have a high viral load, especially in the nose, throat and trachea. Procedures involving the upper aerodigestive tract, such as the bronchoscopy, are considered to carry a high risk of infection. Recommendations from different societies establish certain guidelines for these procedures, suggesting specific safety measures and, where possible, avoiding the performance of rigid bronchospies. Our unit belongs to an interventional pulmonology service of the Public Health System. In order to be able to meet the demand for medical care, the need to perform urgent procedures and the limitation to infrastructure and resources, we began a contingency plan and testing of alternative elements intended to increase the safety of the staff and the patients. This study introduces general measures and new devices included in our work sequence with the purpose of improving biosafety for the health staff and the patient when there is still a need to follow the procedures.
RESUMO
Pulmonary alveolar proteinosis (PAP) is a rare disease characterized by the intra-alveolar accumulation of a proteinaceous phospholipid-laden material called surfactant. Clinically, this disease should be suspected with respiratory failure in association with a crazy paving pattern on high-resolution chest computed tomography. We report a 24-year-old gentleman who was referred to us for a history of respiratory failure, treatment with invasive ventilation and tracheostomy. His blood exams and biochemistry were normal. His infectious and rheumatological panel was negative for a secondary disease. A flexible bronchoscopy with a transbronchial biopsy through a CryoProbe was performed. An anatomopathological analysis was periodic acid-Schiff positive for PAP. A CryoProbe is a recently developed diagnostic tool that improves the diagnostic yield in diffuse lung diseases compared to bronchoscopy with transbronchial biopsy. This method should be considered for patients with diffuse lung disease and PAP.
RESUMO
La Enfermedad Pulmonar Obstructiva Crónica (EPOC) es una enfermedad caracterizada por limitación del flujo aéreo espiratorio donde el atrapamiento aéreo y la hiperinsuflación dinámica conducen a la producción de disnea que muchas veces incapacita al paciente a pesar de un correcto tratamiento farmacológico y de rehabilitación. Los tratamientos quirúrgicos destinados a paliar esta situación como la cirugía de reducción de volumen pulmonar (CRVP) presentan una morbimortalidad que limita su uso. La búsqueda de formas menos invasivas para conseguir el mismo propósito dieron origen a una serie de procedimientos broncoscópicos para la reducción de volumen pulmonar dentro de los cuales, las válvulas endobronquiales (VEB), son las que acumulan mayor desarrollo y experiencia. Si bien los estudios con VEB son heterogéneos y en su conjunto, muestran modestos beneficios en los test de función pulmonar, ejercicio y calidad de vida relacionada con la salud, existe un grupo de pacientes con enfisema pulmonar heterogéneo, cisura interlobar intacta, atrapamiento aéreo severo y baja tolerancia al ejercicio que muestra beneficios estadística y clínicamente significativos. Nuevos estudios se encuentran en desarrollo para dar más peso de evidencia a la acumulada en la actualidad.
Chronic Obstructive Pulmonary Disease (COPD) is characterized by airflow limitation, air trapping and dynamic hyperinflation that lead to disabling dyspnea despite appropriate pharmacologic treatment and pulmonary rehabilitation. Though surgical treatments such as lung transplant surgery and lung volume reduction (LVRS) are available, their high morbidity and mortality limit their use. To avoid these complications multiple procedures for bronchoscopic lung volume reduction have been developed, among which endobronchial valves (EBV) have accumulated the largest amount of evidence. While studies with EBV are heterogeneous and show modest benefits in pulmonary function tests, exercise capacity and quality of life, there is a group of patients with heterogeneous emphysema, intact interlobar fissure, severe air trapping and low exercise tolerance that show a statistically and clinically significant benefits. New studies are under way to further support the growing evidence.
Assuntos
Broncoscopia , Doença Pulmonar Obstrutiva Crônica , EnfisemaRESUMO
INTRODUCTION: Most cases of the 2009 influenza A (H1N1) infection are self-limited, but occasionally the disease evolves to a severe condition needing hospitalization. Here we describe the evolution of the respiratory compromise, ventilatory management and laboratory variables of patients with diffuse viral pneumonitis caused by pandemic 2009 influenza A (H1N1) admitted to the ICU. METHOD: This was a multicenter, prospective inception cohort study including adult patients with acute respiratory failure requiring mechanical ventilation (MV) admitted to 20 ICUs in Argentina between June and September of 2009 during the influenza A (H1N1) pandemic. In a standard case-report form, we collected epidemiological characteristics, results of real-time reverse-transcriptase--polymerase-chain-reaction viral diagnostic tests, oxygenation variables, acid-base status, respiratory mechanics, ventilation management and laboratory tests. Variables were recorded on ICU admission and at days 3, 7 and 10. RESULTS: During the study period 178 patients with diffuse viral pneumonitis requiring MV were admitted. They were 44 ± 15 years of age, with Acute Physiology And Chronic Health Evaluation II (APACHE II) scores of 18 ± 7, and most frequent comorbidities were obesity (26%), previous respiratory disease (24%) and immunosuppression (16%). Non-invasive ventilation (NIV) was applied in 49 (28%) patients on admission, but 94% were later intubated.Acute respiratory distress syndrome (ARDS) was present throughout the entire ICU stay in the whole group (mean PaO2/FIO2 170 ± 25). Tidal-volumes used were 7.8 to 8.1 ml/kg (ideal body weight), plateau pressures always remained < 30 cmH2O, without differences between survivors and non-survivors; and mean positive end-expiratory pressure (PEEP) levels used were between 8 to 12 cm H2O. Rescue therapies, like recruitment maneuvers (8 to 35%), prone positioning (12 to 24%) and tracheal gas insufflation (3%) were frequently applied. At all time points, pH, platelet count, lactate dehydrogenase assay (LDH) and Sequential Organ Failure Assessment (SOFA) differed significantly between survivors and non-survivors. Lack of recovery of platelet count and persistence of leukocytosis were characteristic of non-survivors. Mortality was high (46%); and length of MV was 10 (6 to 17) days. CONCLUSIONS: These patients had severe, hypoxemic respiratory failure compatible with ARDS that persisted over time, frequently requiring rescue therapies to support oxygenation. NIV use is not warranted, given its high failure rate. Death and evolution to prolonged mechanical ventilation were common outcomes. Persistence of thrombocytopenia, acidosis and leukocytosis, and high LDH levels found in non-survivors during the course of the disease might be novel prognostic findings.